Amarin

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push
Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push
Stat
Amarin
Vascepa
FDA
hirings
drug reps
Flag link:
Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?
Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?
Endpoints
Amarin
Vascepa
FDA
Flag link:
Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in
Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in
Fierce Pharma
Amarin
Vascepa
Flag link:
These 6 biotech stocks are promising takeover targets
These 6 biotech stocks are promising takeover targets
Marketwatch
M&A
Sarepta Therapeutics
Amarin
Intercept Pharmaceuticals
Immunomedics
Alder Biopharmaceuticals
Biogen
Flag link:
Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up
Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up
Endpoints
Amarin
Vascepa
FDA
M&A
Flag link:
Diabetes group nods to Vascepa, sending Amarin stock higher
Diabetes group nods to Vascepa, sending Amarin stock higher
Biopharma Dive
ADA
Vascepa
Amarin
diabetes
Flag link:
Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate
Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate
Stat
Amarin
Vascepa
American College of Cardiology
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Roche
SAGE Therapeutics
Ligand Pharmaceuticals
brexanolone
Tecentriq
Jazz Pharmaceuticals
JZP-110
Sanofi
Lexicon Pharmaceuticals
Zynquista
PhaseBio
AstraZeneca
Amarin
Leap Therapeutics
Strongbridge
Flag link:
ACC 2019 preview – Bayer hopes for heart failure panache
ACC 2019 preview – Bayer hopes for heart failure panache
EP Vantage
Bayer
heart failure
Amarin
Esperion
ACC
Vascepa
bempedoic acid
Flag link:
Is Amarin Sitting on a Goldmine?
Is Amarin Sitting on a Goldmine?
Motley Fool
Vascepa
Amarin
Flag link:
Would Pfizer Shareholders Win With an Acquisition of Amarin?
Would Pfizer Shareholders Win With an Acquisition of Amarin?
Motley Fool
Pfizer
Amarin
M&A
Flag link:
Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs
Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs
Fierce Pharma
JPMHC 2019
M&A
Pfizer
Biogen
Amarin
Flag link:
The winners and losers from JPM 2019
The winners and losers from JPM 2019
Biopharma Dive
JPMHC 2019
Loxo Oncology
SAGE Therapeutics
Amarin
FDA
M&A
Flag link:
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
BioSpace
JPMHC 2019
SAGE Therapeutics
SAGE-217
Mersana
Novavax
Denali Therapeutics
AstraZeneca
Amarin
FDA
government shutdown
Flag link:
Pharma's 2019 Prognosis Hinges on These Key Themes
Pharma's 2019 Prognosis Hinges on These Key Themes
Bloomberg
drug pricing
Amarin
Vascepa
IPOs
cancer
Flag link:
The Most Promising Biotech Names Heading Into 2019
The Most Promising Biotech Names Heading Into 2019
Investopedia
biotech
AbbVie
Novavax
Amarin
TG Therapeutics
Flag link:
2 Biotech Stocks Poised for Big Gains in 2019
2 Biotech Stocks Poised for Big Gains in 2019
Motley Fool
Amarin
Vascepa
Novavax
ResVax
Flag link:
Amarin raises $200M ahead of Vascepa push
Amarin raises $200M ahead of Vascepa push
BioCentury
Amarin
Vascepa
Flag link:
Amarin's Vascepa trial stirs data debate as stock drops 10%
Amarin's Vascepa trial stirs data debate as stock drops 10%
Biopharma Dive
Amarin
Vascepa
Flag link:
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Forbes
Amarin
Vascepa
Flag link:

Pages